Insider · CIK 0001658369
Maged Shenouda
Files at RLMD (RELMADA THERAPEUTICS, INC.). First filing Jan 31, 2024, latest Sep 11, 2026.
In brief
Maged Shenouda files SEC Form 4 as CFO at RLMD (RELMADA THERAPEUTICS, INC.). Since Jan 31, 2024, Maged Shenouda has reported 5 open-market buys worth $2.2M and 0 open-market sells worth $0, the latest filed on Sep 11, 2026.
After Maged Shenouda's past buys, the stock beat the S&P 500 by a median 174.9% over six months (n = 3), and 100% of those buys were ahead of the index at six months. InsiderTell labels that a strong record.
The newest scored trade: bought $844k of RLMD on Sep 9, 2026, filed Sep 11, 2026, scored 59 (moderate). In the last 12 months: 3 buys worth $2.0M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RLMD: RELMADA THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 59Moderate | RELMADA THERAPEUTICS, INC. | $844k 200,000 shares | +25% | - | |
| 42Moderate | RELMADA THERAPEUTICS, INC. | $48k 11,665 shares | +1% | +1630% from low-3% from high | |
| 76Notable | RELMADA THERAPEUTICS, INC. | $1.1M 500,000 shares | +173% | +896% from low-26% from high | |
| 65Notable | RELMADA THERAPEUTICS, INC. | $97k 200,000 shares | +226% | +83% from low-87% from high | |
| 72Notable | RELMADA THERAPEUTICS, INC. | $126k 32,675 shares | +1467% | +68% from low-18% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +120,200 | $4.20 | $505k | 920,200 | 33 d ago |
| Sep 10, 2026 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +79,800 | $4.25 | $339k | 1,000,000 | 33 d ago |
| Dec 15, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +11,665 | $4.12 | $48k | 800,000 | Dec 16, 2025 |
| Dec 12, 2025 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Appreciation Rightsderivative | +828,000 | $0.00 | $0 | 828,000 | Dec 16, 2025 |
| Nov 5, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +500,000 | $2.20 | $1.1M | 788,335 | Nov 6, 2025 |
| Jun 26, 2025 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Jun 30, 2025 |
| May 16, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +50,000 | $0.44 | $22k | 138,335 | May 20, 2025 |
| May 19, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +90,000 | $0.49 | $44k | 228,335 | May 20, 2025 |
| May 20, 2025 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +60,000 | $0.52 | $31k | 288,335 | May 20, 2025 |
| Jan 29, 2024 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +10,800 | $3.65 | $39k | 13,028 | Jan 31, 2024 |
| Jan 30, 2024 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +15,000 | $3.89 | $58k | 28,028 | Jan 31, 2024 |
| Jan 31, 2024 | RLMD RELMADA THERAPEUTICS, INC. | POpen-market purchase Common Stock | +6,875 | $4.06 | $28k | 34,903 | Jan 31, 2024 |
| Dec 15, 2023 | RLMD RELMADA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +82,090 | $0.00 | $0 | 82,090 | Dec 19, 2023 |
Questions about Maged Shenouda
Answered from the filings on this page, as of the latest one.
Is Maged Shenouda buying or selling?
In the last 12 months Maged Shenouda reported 3 open-market buys worth $2.0M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $844k of RLMD on Sep 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Maged Shenouda's past buys perform?
Measured from the first close after each filing, the stock beat the S&P 500 by a median 174.9% over six months across 3 past buys, with 100% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Maged Shenouda file Form 4?
Maged Shenouda has filed Form 4 at RLMD (RELMADA THERAPEUTICS, INC.) as Chief Financial Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.